1. 1Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany;
2. 2Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany;
3. 3Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland;
4. 4Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy;
5. 5Center for Omics Sciences, IRCCS San Raffaele Institute, Milano, Italy;
6. 6German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research, Center (DKFZ), Heidelberg, Germany;
7. 7Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany;
8. 8Deutsche Forschungsgemeinschaft Cluster of Excellence 2180 “Image-guided and Functional Instructed Tumor Therapy,” University of Tuebingen, Tuebingen, Germany;
9. 9Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany,
10. 10Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Centre,
11. 11Signalling Research Centres BIOSS and CIBSS – Centre for Integrative Biological, Signalling Studies, and
12. 12CIBSS Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany;
13. 13Novartis Pharma, Basel, Switzerland;
14. 14Max-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany;
15. 15Division of Blood & Marrow Transplant and Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN; and
16. 16The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Johns Hopkins University, Baltimore, MD